Picoplatin is a platinum-based antineoplastic agent in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid tumors.

[1] In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.

[2] However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced small cell lung cancer.

[3] Hopes are now pinned on its use for metastatic colorectal cancer.

This antineoplastic or immunomodulatory drug article is a stub.